DBV Technologies Files 8-K on Financials
Ticker: DBVTF · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1613780
| Field | Detail |
|---|---|
| Company | Dbv Technologies S.A. (DBVTF) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, regulation-fd
TL;DR
DBV Tech filed an 8-K on 3/8/24 for financials. Check it out.
AI Summary
DBV Technologies S.A. filed an 8-K on March 8, 2024, reporting on its financial statements and exhibits. The company, incorporated in France, is involved in the biological products sector, specifically focusing on diagnostic substances. Its principal executive offices are located in Montrouge, France.
Why It Matters
This filing provides an update on DBV Technologies' financial statements and exhibits, which is crucial for investors to assess the company's financial health and performance.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- DBV Technologies S.A. (company) — Registrant
- March 8, 2024 (date) — Date of Report
- France (location) — Jurisdiction of Incorporation
- Montrouge (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits, as well as provide a Regulation FD disclosure.
When was this 8-K report filed?
This 8-K report was filed on March 8, 2024.
Where is DBV Technologies S.A. incorporated?
DBV Technologies S.A. is incorporated in France.
What is the SIC code for DBV Technologies S.A.?
The Standard Industrial Classification (SIC) code for DBV Technologies S.A. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the address of DBV Technologies S.A.'s principal executive offices?
The address of DBV Technologies S.A.'s principal executive offices is 177-181 avenue Pierre Brossolette, 92120 Montrouge, France.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-03-08 16:05:37
Filing Documents
- d754497d8k.htm (8-K) — 29KB
- d754497dex991.htm (EX-99.1) — 7KB
- g754497dsp2.jpg (GRAPHIC) — 6KB
- g754497dsp2a.jpg (GRAPHIC) — 10KB
- g754497snap1.jpg (GRAPHIC) — 5KB
- 0001193125-24-063634.txt ( ) — 225KB
- dbvt-20240308.xsd (EX-101.SCH) — 3KB
- dbvt-20240308_def.xml (EX-101.DEF) — 14KB
- dbvt-20240308_lab.xml (EX-101.LAB) — 22KB
- dbvt-20240308_pre.xml (EX-101.PRE) — 14KB
- d754497d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued March 8, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 8, 2024 DBV TECHNOLOGIES S.A. By: /s/ Virginie Boucinha Name: Virginie Boucinha Title: Chief Financial Officer